🚀 VC round data is live in beta, check it out!
Zhengye Biotechnology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zhengye Biotechnology and similar public comparables like Labiana Health, Vicapsys, Annovis Bio, Vivoryon Therapeutics and more.
Zhengye Biotechnology Overview
About Zhengye Biotechnology
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry, and other vaccines.
Founded
2023
HQ
Employees
277
Website
Sectors
Financials (FY)
EV
$52M
Zhengye Biotechnology Financials
Zhengye Biotechnology reported last fiscal year revenue of $27M and EBITDA of $6M.
In the same fiscal year, Zhengye Biotechnology generated $13M in gross profit, $6M in EBITDA, and $2M in net income.
Zhengye Biotechnology P&L
In the most recent fiscal year, Zhengye Biotechnology reported revenue of $27M and EBITDA of $6M.
Zhengye Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $27M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 49% | XXX | XXX | XXX |
| EBITDA | — | XXX | $6M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 9% | XXX | XXX | XXX |
| Net Profit | — | XXX | $2M | XXX | XXX | XXX |
| Net Margin | — | XXX | 6% | XXX | XXX | XXX |
| Net Debt | — | — | $10M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zhengye Biotechnology Stock Performance
Zhengye Biotechnology has current market cap of $47M, and enterprise value of $52M.
Market Cap Evolution
Zhengye Biotechnology's stock price is $0.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $47M | 11.9% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZhengye Biotechnology Valuation Multiples
Zhengye Biotechnology trades at 1.9x EV/Revenue multiple, and 8.4x EV/EBITDA.
Zhengye Biotechnology Financial Valuation Multiples
As of April 11, 2026, Zhengye Biotechnology has market cap of $47M and EV of $52M.
Equity research analysts estimate Zhengye Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhengye Biotechnology has a P/E ratio of 28.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $47M | XXX | $47M | XXX | XXX | XXX |
| EV (current) | $52M | XXX | $52M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 20.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.9x | XXX | XXX | XXX |
| P/E | — | XXX | 28.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 27.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zhengye Biotechnology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zhengye Biotechnology Margins & Growth Rates
Zhengye Biotechnology's revenue in the last fiscal year declined by (12%).
Zhengye Biotechnology's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Zhengye Biotechnology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (12%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (41%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zhengye Biotechnology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Labiana Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Vicapsys | XXX | XXX | XXX | XXX | XXX | XXX |
| Annovis Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhengye Biotechnology M&A Activity
Zhengye Biotechnology acquired XXX companies to date.
Last acquisition by Zhengye Biotechnology was on XXXXXXXX, XXXXX. Zhengye Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zhengye Biotechnology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZhengye Biotechnology Investment Activity
Zhengye Biotechnology invested in XXX companies to date.
Zhengye Biotechnology made its latest investment on XXXXXXXX, XXXXX. Zhengye Biotechnology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zhengye Biotechnology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zhengye Biotechnology
| When was Zhengye Biotechnology founded? | Zhengye Biotechnology was founded in 2023. |
| Where is Zhengye Biotechnology headquartered? | Zhengye Biotechnology is headquartered in China. |
| How many employees does Zhengye Biotechnology have? | As of today, Zhengye Biotechnology has over 277 employees. |
| Who is the CEO of Zhengye Biotechnology? | Zhengye Biotechnology's CEO is Songlin Song. |
| Is Zhengye Biotechnology publicly listed? | Yes, Zhengye Biotechnology is a public company listed on Nasdaq. |
| What is the stock symbol of Zhengye Biotechnology? | Zhengye Biotechnology trades under ZYBT ticker. |
| When did Zhengye Biotechnology go public? | Zhengye Biotechnology went public in 2025. |
| Who are competitors of Zhengye Biotechnology? | Zhengye Biotechnology main competitors are Labiana Health, Vicapsys, Annovis Bio, Vivoryon Therapeutics. |
| What is the current market cap of Zhengye Biotechnology? | Zhengye Biotechnology's current market cap is $47M. |
| What is the current revenue of Zhengye Biotechnology? | Zhengye Biotechnology's last fiscal year revenue is $27M. |
| What is the current EV/Revenue multiple of Zhengye Biotechnology? | Current revenue multiple of Zhengye Biotechnology is 1.9x. |
| Is Zhengye Biotechnology profitable? | No, Zhengye Biotechnology is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.